It is unclear whether more timely cancer diagnosis brings favourable outcomes, with much of the previous evidence, in some cancers, being equivocal. We set out to determine whether there is an association between time to diagnosis, treatment and clinical outcomes, across all cancers for symptomatic presentations.
Monocytes are a group of immune cells that originate in bone marrow and are released into peripheral blood, where they circulate for several days1,2. They belong to the mononuclear-phagocyte system, which also include macrophages, dendritic cells and their bone-marrow precursors3,4,5. Monocytes represent 5–10% of peripheral leucocytes and are probably best known for serving as a systemic reservoir of myeloid precursors that are needed for the renewal of tissue macrophages and dendritic cells6,7,8,9. However, they also have other well documented functions in immune response against infection10,11,12,13 and in pathogenesis of several inflammatory disorders. Although initially perceived as a homogeneous population, it has become increasingly apparent that monocytes display considerable heterogeneity with respect to their phenotype and function1,2,14,15.
Immunoglobulin G (IgG) antibody subclasses play major roles in the control of bacterial and viral infections, the killing of tumour cells during antibody therapy and the pathological destruction of healthy tissues in autoimmune diseases. As a result of their potency and range of actions, antibodies have become one of the most rapidly growing classes of human therapeutics in recent years, particularly in cancer treatments.
Covid-19 can involve multiple organs including the nervous system. We sought to characterize the neurologic manifestations, their risk factors, and associated outcomes in hospitalized patients with Covid-19.
Optical biosensors have led to significant advancements in virus detection and imaging capabilities. Coupled with advanced instrumentation, they have enabled higher sensitivities while increasing the rate at which samples can be tested. These techniques can be developed into point-of-care (POC) diagnostics for viral detection and are promising alternatives to detect COVID-19.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiology of coronavirus disease 2019 (COVID-19), is readily transmitted person to person. Optimal control of COVID-19 depends on directing resources and health messaging to mitigation efforts that are most likely to prevent transmission, but the relative importance of such measures has been disputed.
Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has caused a global pandemics. To facilitate the detection of SARS-CoV-2 infection, various RT-LAMP assays using 19 sets of primers had been developed, but never been compared.
Lateral flow devices for asymptomatic mass testing are proving controversial. At the heart of the matter is a flawed process, with the decision to implement society-wide “Moonshot” testing made before robust field evaluations of the tests were completed. Subsequent selective emphasis of unrealistic performance estimates has caused confusion. Little surprise we are now in a mess.
Acute coronavirus disease 2019 (COVID-19) is primarily diagnosed via reverse transcription-polymerase chain reaction (RT-PCR) detection of viral genetic material. However, considering the three primary modes of transmission of SARS-Cov-2 i.e., contact, droplet and aerosol routes, various types of samples have been suggested for the purpose of detection.
For effectively suppressing COVID-19’s spread, contact tracing has been widely used to identify, isolate, and follow-up with those who have come in close contact with an infected person (or “close contacts”). Traditionally, contact tracers in local health offices interview an infected person to identify visited places (or hotspots) and then check any close contacts. For the accurate recall of travel history, several countries including South Korea corroborate multiple data sources, such as cell location or credit card transactions.